rethinkPeptides Search
Menu
Study breakdown

GLP-1 Drug Treatment Improves Mental Health Over 4 Months in Weight Loss Study

evidence
The takeaway

Four months of GLP-1 RA treatment for weight loss was associated with improvements in mental health outcomes including anxiety, depression, and quality of life measures.

Mind improves too

GLP-1 drugs improved anxiety, depression, and quality of life alongside weight loss — reassuring against mental health safety concerns

What the researchers found

Four months of GLP-1 RA weight loss treatment associated with mental health improvements including reduced anxiety, depression, and improved quality of life.

Why it matters

Mental health concerns have been raised about GLP-1 drugs. Showing they IMPROVE mental health provides critical reassurance.

How the study worked

Assessment of mental health outcomes during 4-month GLP-1 RA weight loss treatment.

What this study cannot tell us

4-month follow-up. Cannot separate weight loss effects from direct drug effects. Observational.

How to read the evidence

Observational mental health assessment during treatment.

When this study was published

Published in 2025.

The bigger picture

GLP-1 drugs improve both physical and mental health — addressing the whole person rather than just metabolic numbers.

Questions still open

  • Do mental health improvements persist long-term?
  • Which mental health outcomes improve most?
  • Would patients with pre-existing mental illness show the same benefits?

Common questions

Do GLP-1 drugs help mental health?
This study found patients on GLP-1 drugs had less anxiety, less depression, and better quality of life after 4 months — providing reassurance against mental health concerns.
Could GLP-1 drugs cause depression?
This study found the opposite — mental health improved during treatment. Combined with other studies, the evidence suggests GLP-1 drugs are psychiatrically safe and potentially beneficial.

Read the original research

Mental health changes after 4 months of weight loss treatment with the glucagon-like peptide-1 analogue liraglutide 3.0 mg.

Diabetes, obesity & metabolism, 28(3), 2095-2104

Citation

Kuckuck, Susanne; van Gerwen, Nina; Oosterman, Johanneke E; Savas, Mesut; Kavousi, Maryam; Penninx, Brenda W J H; Boon, Mariëtte R; van Rossum, Elisabeth F C. (2026). Mental health changes after 4 months of weight loss treatment with the glucagon-like peptide-1 analogue liraglutide 3.0 mg.. Diabetes, obesity & metabolism, 28(3), 2095-2104. https://doi.org/10.1111/dom.70393